zenocutuzumab

08/01/2021 - "Zenocutuzumab, an investigational bispecific antibody, has shown early efficacy in an ongoing phase I/II study of patients with tumors harboring NRG1 fusions. "
01/01/2020 - "The aims of this analysis were to characterize the population pharmacokinetics of MCLA-128 in patients with various solid tumors, to evaluate patient-related factors that affect the disposition of MCLA-128, and to assess whether flat dosing is appropriate. "
12/01/2019 - "MCLA-128 Fights NRG1 Fusion-Positive Cancers."
12/01/2018 - "The xenograft tumor growth model consisted of a tumor compartment with a zero-order growth rate and a first-order dying rate, both affected by MCLA-128. "
01/01/2022 - "Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements."

09/15/2022 - "Although an early clinical study failed to demonstrate benefit of adjuvant trastuzumab for ERBB2-low disease, several novel anti-ERBB2 therapies have shown efficacy in ERBB2-low breast cancer, including the antibody-drug conjugate trastuzumab deruxtecan in a phase 3 trial, and trastuzumab duocarmazine and the bispecific antibody zenocutuzumab in early-phase studies. "
01/01/2022 - "Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in NRG1 Fusion-Positive, Estrogen Receptor-Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor."

12/01/2019 - "Two patients with KRAS-wild-type pancreatic ductal carcinoma and NRG1 fusions received the bispecific antibody MCLA-128, which led to tumor shrinkage. "